Xilio Therapeutics announced fourth quarter and full year 2025 financial results on March 23, 2026, reporting collaboration and license revenue of $13.7 million for Q4 and net income of $10.4 million, alongside a cash position of $137.5 million as of December 31, 2025. The company provided pipeline updates on XTX501 and masked T cell engagers, with cash runway extended through the end of 2027.
Key takeaways
Cash and cash equivalents $137.5 million as of December 31, 2025, compared to $55.3 million as of December 31, 2024.
Q4 2025 collaboration and license revenue $13.7 million vs $1.7 million in Q4 2024.
FY 2025 collaboration and license revenue $43.8 million vs $6.3 million in FY 2024.
Q4 2025 net income $10.4 million vs net loss $13.1 million in Q4 2024.
FY 2025 net loss $35.0 million vs $58.2 million in FY 2024.
XTX501 IND submission planned mid-2026, Phase 1 initiation second half 2026.
$35.8 million gross proceeds from Series B warrant exercises in January 2026; $40.0 million from February 2026 follow-on offering.